Brief: Rain Oncology Announces Topline Results From Phase 3 MANTRA Trial Of Milademetan
22/05/2023 13:30
May 22 (Reuters) - Rain Oncology Inc RAIN.O :
* RAIN ONCOLOGY ANNOUNCES TOPLINE RESULTS FROM PHASE 3
MANTRA
TRIAL OF MILADEMETAN FOR THE TREATMENT OF DEDIFFERENTIATED
LIPOSARCOMA
* RAIN ONCOLOGY INC - PHASE 3 MANTRA TRIAL DID NOT MEET
PRIMARY
ENDPOINT OF PROGRESSION FREE SURVIVAL VERSUS. STANDARD OF CARE
* RAIN ONCOLOGY INC - MEDIAN PFS WAS 3.6 MONTHS FOR
MILADEMETAN
VERSUS 2.2 MONTHS FOR TRABECTEDIN WITH A HAZARD RATIO OF 0.89
* RAIN ONCOLOGY INC - VERY DISAPPOINTED IN OUTCOME OF MANTRA
TRIAL, AS RESULTS DID NOT CLOSELY MIRROR PRIOR CLINICAL RESULTS
IN PATIENTS WITH DD LPS
Source text for Eikon: ID:nGNX5ZMmD2
Further company coverage: RAIN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million